AEON Biopharma
AEON
85 hedge funds and large institutions have $248M invested in AEON Biopharma in 2022 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 13 increasing their positions, 16 reducing their positions, and 8 closing their positions.
63% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 8
12% more capital invested
Capital invested by funds: $222M → $248M (+$26.3M)
5% more funds holding
Funds holding: 81 → 85 (+4)
0.07% more ownership
Funds ownership: 1.17% → 1.24% (+0.07%)
19% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CIM
Cowen Investment Management
New York
|
+$5.72M |
| 2 |
WCMNY
Westchester Capital Management (New York)
Valhalla,
New York
|
+$5.5M |
| 3 |
MC
Meteora Capital
Boca Raton,
Florida
|
+$5.26M |
| 4 |
D.E. Shaw & Co
New York
|
+$3.87M |
| 5 |
DFCM
Dark Forest Capital Management
San Juan,
Puerto Rico
|
+$3.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$4.68M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$4.12M |
| 3 |
Parallax Volatility Advisers
San Francisco,
California
|
-$3.87M |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
-$3.43M |
| 5 |
Calamos Advisors
Naperville,
Illinois
|
-$2.46M |
AEON Hedge Fund Activity: Q4 2022 in Review
85 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in AEON Biopharma (AEON) for Q4 2022, worth a combined $248M — up 12% from $222M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new AEON positions and 8 closed out — a net gain of 5 holders — while 13 added to existing stakes and 16 trimmed.
The largest buyer was Cowen Investment Management, opening a new position worth an estimated $5.72M. The largest seller was UBS O'Connor, exiting entirely with an estimated $4.68M sold.
- 85 institutional investors held AEON Biopharma (AEON) as of Q4 2022, up from 81 in Q3 2022.
- Funds reported $248M of AEON Biopharma stock for Q4 2022, up 12% quarter-over-quarter.
- 13 funds opened new AEON Biopharma positions in Q4 2022 and 8 closed out, a net change of +5 holders.
- The largest AEON Biopharma buyer in Q4 2022 was Cowen Investment Management, an estimated $5.72M added.
- The largest AEON Biopharma seller in Q4 2022 was UBS O'Connor, an estimated $4.68M sold.
Based on aggregated 13F filings for Q4 2022.